CN118178476A - 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用 - Google Patents
阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用 Download PDFInfo
- Publication number
- CN118178476A CN118178476A CN202410418022.3A CN202410418022A CN118178476A CN 118178476 A CN118178476 A CN 118178476A CN 202410418022 A CN202410418022 A CN 202410418022A CN 118178476 A CN118178476 A CN 118178476A
- Authority
- CN
- China
- Prior art keywords
- acremonium
- preparation
- fat
- application
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 title claims abstract description 31
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 28
- 230000013872 defecation Effects 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000001737 promoting effect Effects 0.000 title claims abstract description 11
- 238000007599 discharging Methods 0.000 title description 2
- 229940079593 drug Drugs 0.000 title description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 claims abstract description 16
- 238000009825 accumulation Methods 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims description 19
- 150000002632 lipids Chemical class 0.000 claims description 7
- 239000002207 metabolite Substances 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 241000702462 Akkermansia muciniphila Species 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 210000000813 small intestine Anatomy 0.000 description 36
- 235000014113 dietary fatty acids Nutrition 0.000 description 24
- 229930195729 fatty acid Natural products 0.000 description 24
- 239000000194 fatty acid Substances 0.000 description 24
- 150000004665 fatty acids Chemical class 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 16
- 230000029142 excretion Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000002550 fecal effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 210000003240 portal vein Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 241000778935 Akkermansia muciniphila ATCC BAA-835 Species 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了阿克曼菌在制备用于促进排便、排脂或减少肠道脂肪吸收的药物中的应用。本发明所提供的阿克曼菌及其制剂具有增加排便和排脂，减少肠道对脂肪吸收和减少内脏脂肪蓄积的作用。
Description
技术领域
本发明属于生物医药领域，尤其涉及阿克曼菌在用于制备促进排便、排脂或减少肠道脂肪吸收和内脏脂肪蓄积的药物中的应用。
背景技术
自2004年首次发现阿克曼菌（Akk）以来，大量研究报道指出阿克曼菌可以缓解代谢性疾病，相关专利申请了阿克曼菌在代谢病症中的作用，包括代谢综合征、膜岛素缺乏或膜岛素抵抗相关的病症、糖尿病（例如， 2 型糖尿病）、葡糖耐受不良、异常脂质代谢、动脉粥样硬化、高血压、心脏病、中风、非酒精性脂肪肝病、高血糖症、肝性脂肪变性、血脂异常、与超重和肥胖症相关的免疫系统功能障碍、心血管疾病、高胆固醇、升高的甘油三酸醋、眸喘、睡II民呼吸暂停、骨关节炎、神经变性、胆囊疾病、X 综合征、炎症性和免疫性病症、致动脉粥样化性血脂异常和癌症。但尚无报道阿克曼菌在促排便、排脂方面的作用。
发明内容
本发明的目的是提供了阿克曼菌用于制备促进排便、排脂或减少肠道脂肪吸收的药物的应用。
1. 使用实验动物小鼠进行阿克曼菌灌胃，首次发现阿克曼菌增加了小鼠的粪便排泄量，促进了排脂量，减少了小肠吸收脂肪的量，减少了门静脉吸收脂肪，减少了内脏脂肪蓄积。
2. 使用脂肪酸（BODIPY-C12）对小鼠的小肠进行体内孵育及对人的小肠进行体外孵育，结果证实阿克曼菌可以减少小肠的脂肪吸收。说明在小鼠和人肠道阿克曼菌均有效。
3. 将阿克曼菌裂解组分进行按分子量大小进行分离，结果发现小于100kDa组分具有减少小肠脂肪吸收的作用。该组分含蛋白/多肽、糖类、脂类、小分子代谢物或复合物。
4. 使用质谱仪鉴定的阿克曼菌裂解成分中的蛋白/多肽，小于100kDa的部分至少含有三种阿克曼菌蛋白，分别是Amuc-0318、Amuc-0405和Amuc-1240。
综上，本发明发现阿克曼菌可以用于减少动物和人脂肪吸收、增加粪便排泄、促进脂肪排泄或减少内脏脂肪蓄积。
本发明提供如下技术方案在于：
阿克曼菌在制备用于促进排便、排脂、减少肠道脂肪吸收或减少内脏脂肪蓄积的药物的应用。
优选地，所述的促进排便为增加排便量。
所选地，所述的阿克曼菌可以是活菌、巴氏灭活菌。
优选地所述的阿克曼菌用于制备药物的用途，可以是活菌、巴氏灭活菌、菌体成分、分泌物或代谢物。
优选地，所述的阿克曼菌为Akkermansia muciniphila ATCC BAA-835或任何阿克曼菌亚株。
相比现有技术，本发明的有益效果在于：
1.本发明发现阿克曼菌活菌、巴氏灭活菌或小于100kDa组分具有减少小肠脂肪吸收的能力
2.食用阿克曼菌可以用于减少动物和人脂肪吸收、增加粪便排泄、促进脂肪排泄或减少内脏脂肪蓄积。
3.本发明所述的主要对象为人和动物的小肠，所发现的功能基于阿克曼菌对小肠的作用，小肠又分为十二指肠、空肠和回肠，凡是针对这三类肠段的都属于小肠范围。
4. 本发明发现阿克曼菌可以减少动物和人脂肪吸收、增加粪便排泄、促进脂肪排泄、减少内脏脂肪蓄积。生物学内容上的相通性，通过增加阿克曼菌或提升肠道阿克曼菌含量的方法，达到本发明所描述的应用，均属于本专利的权利要求。凡使用活菌/灭活菌/菌体/培养物/分泌物等成分实现本项目目标的，也均具有本专利所发现的功能。因此，本发明认为，与肠道阿克曼菌丰度或含量相关的小肠脂肪吸收、排泄或粪便排泄或内脏脂肪蓄积的内容，均是基于本发现而延伸的。
附图说明
图1为阿克曼菌增加受试者的排便量、促进排便和减少脂肪吸收结果图。
图2为阿克曼菌减少小鼠肠道脂肪吸收结果图、减少内脏脂肪结果图。
图3为阿克曼菌减少人的小肠脂肪吸收结果图。
图4为阿克曼菌小于100kDa的组分减少小肠脂肪吸收效果图、部分蛋白鉴定的结果图。
具体实施方式
下面，结合附图以及具体实施方式，对本发明做进一步描述，需要说明的是，在不相冲突的前提下，以下描述的各实施例之间或各技术特征之间可以任意组合形成新的实施例。
实施例1
阿克曼菌溶液增加受试者的排便量、促进排便和排脂。
将C57/BL小鼠随机分为两组，即对照组（PBS组）和阿克曼菌处理组（Akk组）。阿克曼菌组每天灌胃200ul 阿克曼菌溶液（含4*10^8 阿克曼菌菌），对照组灌胃200ul PBS溶液。小鼠自由进食高脂饲料，自由饮用灭菌自来水，观察周期18周。在18周后，收集每只小鼠的24小时粪便，同时进行称重，随后检测粪便中的脂肪含量。进一步检测小肠中的脂肪和门静脉的脂肪含量。在本发明中所有实施方式中的阿克曼菌均为Akkermansia muciniphilaATCC BAA-835。
结果：本发明发现，相较于PBS组而言，Akk组小鼠的粪便排泄量增加（图1A）排脂量增加（图1B），小肠吸收脂肪的量减少（图1C和D）。门静脉回收肠道吸收的脂肪，阿克曼菌处理减少了门静脉脂肪回收量。（图1D右图）。
实施例2
阿克曼菌减少小鼠小肠脂肪吸收
将C57/BL小鼠分为两组。即对照组（PBS组）和阿克曼菌处理组（Akk组）。首先使用戊巴比妥钠麻醉小鼠，解剖小鼠并游离出10cm小肠，小肠两端用血管钳夹闭。将200ul 阿克曼菌和1ml 脂肪酸C12（一种绿色荧光标记的脂肪酸）注射进入肠道。对照组操作一致，注射物品为200ul PBS和1ml脂肪酸C12。同时设立空白对照组，操作与上述一致，注射物品为1.2ml PBS溶液。10分钟后，将小鼠小肠取出，使用4%多聚甲醛固定15分钟后进行病理切片（切片厚度10um），随后在荧光显微镜下拍照。此外，我们收集实施例1中的小鼠的内脏脂肪并称重，随后使用4%多聚甲醛对小鼠内脏脂肪固定24小时，然后进行石蜡包埋后病理切片（切片厚度3um），进一步的将切片进行苏木精-伊红染色（HE染色）后显微镜拍照。
结果：空白对照组（PBS）由于没有荧光标记的脂肪酸加入，因此显示背景色。对照组（脂肪酸C12）的小肠显示绿色荧光，这说明脂小肠吸收了荧光标记的脂肪酸。脂肪酸C12+Akk组，脂肪酸荧光颜色相比对照要少和弱（图2A-B），说明阿克曼菌减少了小肠吸收荧光标记的脂肪酸。测量小鼠内脏脂肪（以附睾脂肪为例），显示Akk组小鼠的内脏脂肪重量显著低于对照PBS组。同时，Akk组小鼠的内脏脂肪的细胞大小也显著小于PBS组。这说明阿克曼菌可以通过减少肠道吸收脂肪进而减少内脏脂肪蓄积（图2C-D）。
实施例3
阿克曼菌减少人的小肠脂肪吸收
同理，本发明使用临床志愿者的小肠样本进行测试（实验伦理被暨南大学附属第一医院批准，备案号为KY-2023-229）。收到新鲜的人类小肠样本，均匀的剪成1cm左右的小肠段。随后放入6孔板中，空白对照组加入5ml PBS，对照组加入5 ml脂肪酸C12，实验组加入5ml脂肪酸C12和阿克曼菌。在10分钟后，取出小肠段，使用4%多聚甲醛固定15分钟后进行病理切片（切片厚度10um），随后在荧光显微镜下拍照。
结果：空白对照组（PBS）由于没有加入荧光标记的脂肪酸，因此显示为背景色。对照组（脂肪酸C12）的小肠显示出绿色荧光，这说明小肠吸收了荧光标记的脂肪酸。脂肪酸C12+Akk组，荧光较少较弱（图3）。这说明加入阿克曼菌减少了人小肠对脂肪酸的吸收。
实施例4
阿克曼菌裂解组分中，小于100kDa的组分可以减少小肠脂肪吸收
本发明使用超声破碎仪对阿克曼菌进行破碎，收集破碎后的成分，随后使用超滤管（100kDa规格），将阿克曼菌组分分为Akk>100kDa和Akk<100kDa。随后将小鼠随机分为4组。首先使用戊巴比妥钠麻醉小鼠，解剖小鼠并游离出10cm小肠，小肠两端用血管钳夹闭。（1）将200ul 阿克曼菌和1ml 脂肪酸C12（一种绿色荧光标记的脂肪酸）注射进入肠道。（2）将200ul Akk <100kDa组分和1ml 脂肪酸C12注射进入肠道（3）对照组操作一致，注射物品为200ul PBS和1ml脂肪酸C12；（4）同时设立空白对照组，操作与上述一致，注射物品为1.2ml PBS溶液。10分钟后，将小鼠小肠取出，使用4%多聚甲醛固定15分钟后进行病理切片（切片厚度10um），随后在荧光显微镜下拍照。
结果：空白对照组（PBS）小肠无明显绿色荧光，显示为背景色。对照组（脂肪酸C12）的小肠显示绿色荧光，说明小肠吸收了荧光标记的脂肪酸。Akk处理组（脂肪酸C12+Akk），绿色荧光比对照组减少减弱（图4A和B）。小于100kda Akk组分处理组（脂肪酸C12+Akk<100kDa）也显示绿色荧光比对照组减少减弱（图4A和B）。这说明阿克曼菌和小于100kDa组分均抑制了小肠对脂肪的吸收。
Akk<100kDa组分至少含三种蛋白
为了进一步鉴定小于100kDa 阿克曼菌组分中的蛋白。本发明其中蛋白进行PAGE胶分离。并进行蛋白质谱检测。
结果：蛋白质谱结果显示，小于100kDa组分中，至少高表达三种阿克曼菌蛋白，分别为Amuc-0318、Amuc-0405和Amuc-1240（图4C）。
上述实施方式仅为本发明的优选实施方式，不能以此来限定本发明保护的范围，本领域的技术人员在本发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
Claims (5)
1.阿克曼菌或阿克曼菌制剂的下述任何一种应用：
A1）所述阿克曼菌或阿克曼菌制剂在制备促进排便的药物的应用；
A2）所述阿克曼菌或阿克曼菌制剂在制备增加排便量的药物的应用
A3）所述阿克曼菌或阿克曼菌制剂在制备促进排脂的药物的应用；
A4）所述阿克曼菌或阿克曼菌制剂在制备减少肠道脂肪吸收的药物的应用；
A5）所述阿克曼菌或阿克曼菌制剂在制备减少内脏脂肪蓄积的药物中的应用。
2.如权利要求1所述的应用，其特征在于：所述的阿克曼菌制剂为活菌、巴氏灭活菌、菌体成分、分泌成分或代谢产物。
3.如权利要求2所述的应用，其特征在于：所述菌体成分、分泌成分或代谢产物，包括其中的小分子、肽类、糖类、脂类、核酸类或糖脂/糖蛋白/脂蛋白的复合物。
4.如权利要求2所述的应用，其特征在于：所述菌体成分、分泌成分中，包含有Amuc-0318、Amuc-0405和Amuc-1240。
5. 如权利要求1-2任一项所述的应用，其特征在于：所述的阿克曼菌为Akkermansia muciniphila属。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410402949 | 2024-04-03 | ||
| CN2024104029498 | 2024-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118178476A true CN118178476A (zh) | 2024-06-14 |
Family
ID=91396648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410418022.3A Pending CN118178476A (zh) | 2024-04-03 | 2024-04-09 | 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118178476A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150306152A1 (en) * | 2012-11-19 | 2015-10-29 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| US20180250347A1 (en) * | 2015-09-10 | 2018-09-06 | Université Catholique de Louvain | Use of pasteurized akkermansia for treating metabolic disorders |
| US20220031769A1 (en) * | 2018-09-27 | 2022-02-03 | Sph Sine Pharmaceutical Laboratories Co., Ltd | Strain for preventing and treating metabolic diseases and use thereof |
| US20230405076A1 (en) * | 2020-11-09 | 2023-12-21 | The Akkermansia Compan | Composition comprising akkermansia muciniphila and green tea extract |
-
2024
- 2024-04-09 CN CN202410418022.3A patent/CN118178476A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150306152A1 (en) * | 2012-11-19 | 2015-10-29 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| US20180250347A1 (en) * | 2015-09-10 | 2018-09-06 | Université Catholique de Louvain | Use of pasteurized akkermansia for treating metabolic disorders |
| US20220031769A1 (en) * | 2018-09-27 | 2022-02-03 | Sph Sine Pharmaceutical Laboratories Co., Ltd | Strain for preventing and treating metabolic diseases and use thereof |
| US20230405076A1 (en) * | 2020-11-09 | 2023-12-21 | The Akkermansia Compan | Composition comprising akkermansia muciniphila and green tea extract |
Non-Patent Citations (4)
| Title |
|---|
| DENGLONG SUN 等: "Lacidophilin tablets alleviate constipation through regulation of intestinal microflora by promoting the colonization of Akkermansia sps", SCIENTIFIC REPORTS, vol. 14, no. 1, 26 March 2024 (2024-03-26), pages 7152 * |
| JUNCHAO WANG，等: ""The outer membrane protein Amuc_1100 of Akkermansia muciniphila promotes intestinal 5-HT biosynthesis and extracellular availability through TLR2 signalling"", FOOD FUNCT., vol. 12, no. 8, 26 April 2021 (2021-04-26), pages 3597 - 3610 * |
| YANAN GUO 等: "Latilactobacillus sakei Furu2019 and stachyose as probiotics, prebiotics, and synbiotics alleviate constipation in mice", FONT. NUTR., vol. 9, 5 January 2023 (2023-01-05) * |
| 苗壮壮: "乳双歧杆菌Probio-M8对自闭症模型小鼠行为、肠道菌群及其代谢物质的影响", 硕士学位论文全文数据库工程科技I辑, no. 2023, 15 June 2023 (2023-06-15), pages 35 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fotschki et al. | Fructo-oligosaccharides and pectins enhance beneficial effects of raspberry polyphenols in rats with nonalcoholic fatty liver | |
| Mao et al. | Glycated fish protein supplementation modulated gut microbiota composition and reduced inflammation but increased accumulation of advanced glycation end products in high-fat diet fed rats | |
| WO2023036203A1 (zh) | Cs-4发酵菌丝体杂聚多糖及其制备方法与用途 | |
| Reboredo-Rodríguez et al. | Applicability of an in-vitro digestion model to assess the bioaccessibility of phenolic compounds from olive-related products | |
| CN110628859A (zh) | 一种糖基化牡蛎肽及其制备方法 | |
| CN108904523A (zh) | 魔芋葡甘露聚糖用于治疗和改善肥胖症的应用 | |
| Benincasa et al. | Dried destoned virgin olive pomace: a promising new by-product from pomace extraction process | |
| Zhao et al. | Hydrolyzed bound phenolics from rice bran alleviate hyperlipidemia and improve gut microbiota dysbiosis in high-fat-diet fed mice | |
| Fernández-Jalao et al. | Impact of high-pressure processed onion on colonic metabolism using a dynamic gastrointestinal digestion simulator | |
| Jammes et al. | Pro-inflammatory cytokine priming and purification method modulate the impact of exosomes derived from equine bone marrow mesenchymal stromal cells on equine articular chondrocytes | |
| Yao et al. | Effect of Paecilomyces cicadae polysaccharide Pc0-1 on cyclophosphamide-induced immunosuppression and regulation of intestinal flora in mice | |
| CN118178476A (zh) | 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用 | |
| Zhang et al. | Phenolamide extract of apricot bee pollen alleviates glucolipid metabolic disorders and modulates the gut microbiota and metabolites in high-fat diet-induced obese mice | |
| CN117866798A (zh) | 发酵乳杆菌glf-217及其在溃疡性结肠炎、高脂血症和降低器官损伤中的应用 | |
| Teixeira et al. | Characterization of the Effect of a Novel Production Technique for ‘Not from Concentrate’Pear and Apple Juices on the Composition of Phenolic Compounds | |
| WO2013187381A1 (ja) | Ｐｐａｒ活性化剤の製造方法及びｐｐａｒ活性化剤 | |
| Zheng et al. | Effects of Four Extraction Methods on Structure and In Vitro Fermentation Characteristics of Soluble Dietary Fiber from Rape Bee Pollen | |
| Li et al. | Toxicological evaluation of water-extract sericin from silkworm (Bombyx mori) in pregnant rats and their fetus during pregnancy | |
| Yang et al. | Soybean protein hydrolysate improves plasma and liver lipid profiles in rats fed high-cholesterol diet | |
| CN106173853B (zh) | 一种降血脂的营养组合物及其应用 | |
| Nieto et al. | Implication of the polymeric phenolic fraction and matrix effect on the antioxidant activity, bioaccessibility, and bioavailability of grape stem extracts | |
| CN114224908A (zh) | 蛹虫草多糖在制备调节高脂饮食引起的肠道菌群和代谢物紊乱产品中的应用 | |
| Shi et al. | Pomegranate peel polyphenols interaction with intestinal flora and its metabolic transformation | |
| EP3766498A1 (en) | Use of bio-transformed bear bile powder in preparation of anti-inflammatory drugs | |
| Babji | Swiftlet’ s Nest as Potential Prebiotic Compound for the Gut Beneficial Bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |